|
| Status |
Public on Nov 01, 2021 |
| Title |
E784 |
| Sample type |
RNA |
| |
|
| Source name |
KPfC pancreatic tumor
|
| Organism |
Mus musculus |
| Characteristics |
tissue: KPfC orthotopic pancreatic tumor
treatment: TP-0903+Gemcitabine
|
| Treatment protocol |
For KPfC endpoint study, therapy was initiated at day 10 post tumor cell injection. Treatments consist of 8 groups: vehicle; TP-0903, 25 mg/kg, daily, oral gavage; gemcitabine, 25 mg/kg, ip, 3x/week; anti-PD1 antibody (clone: RMP14-1), 5 mg/kg, ip, twice per week; TP-0903+gemcitabine; TP-0903+anti-PD1; TP-0903+gemcitabine+anti-PD1; gemcitabine+anti-PD1. All mice were sacrificed on Day 35.
|
| Growth protocol |
0.5 × 10^6 KPfC BMF-A3 cells were implanted orthotopically into WT C57BL/6 mice. Ultrasound was done on a cohort of animals to confirm tumor burden before therapy was initiated.
|
| Extracted molecule |
total RNA |
| Extraction protocol |
KPfC tumor tissues from orthotopic endpoint experiment were lysed in RLT lysis buffer and purified according to the manufacturer’s instructions (QIAGEN). Quality control was performed with Agilent Bioanalyser.
|
| Label |
NanoString nCounter probes
|
| Label protocol |
NA
|
| |
|
| Hybridization protocol |
Total RNA from each sample was hybridized to the CodeSet nCounter PanCancer Immune Profiling Panel, Mouse.
|
| Scan protocol |
The scanning was processed on the NanoString Technologies nCounter Sprint Profiler.
|
| Description |
E784
|
| Data processing |
We used the nSolver Analysis Software 4.0 (NanoString Technologies).
Samples were normalized based on the geometric means of the supplied positive controls and the panel of housekeeping genes.
|
| |
|
| Submission date |
Sep 30, 2021 |
| Last update date |
Nov 02, 2021 |
| Contact name |
Yuqing Zhang |
| E-mail(s) |
yuqing.zhang@utsouthwestern.edu
|
| Organization name |
UTSouthwestern Medical Center
|
| Department |
Surgery
|
| Lab |
Rolf Brekken
|
| Street address |
6000 Harry Hines Blvd
|
| City |
Dallas |
| State/province |
TX |
| ZIP/Postal code |
75390 |
| Country |
USA |
| |
|
| Platform ID |
GPL30298 |
| Series (1) |
| GSE185110 |
Transcriptomic analysis of orthotopic pancreatic tumors treated by Axl inhibitor TP-0903 or combination with chemo/immunotherapy using the nCounter PanCancer Immune Profiling panel (Nanostring Technologies) [mouse] |
|
